The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Open accessAbstract
BACKGROUND: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1. METHODS: In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing. RESULTS: A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients. CONCLUSIONS: In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Research works printed but not linked: 3
- 10.2307/2281868 · DOI · Paper page
- Berger RL, 1996, Am Stat, 50, 314
- Behr DS, 2014, Int J Clin Exp Pathol, 7, 7610
Cited by
Sorted by citations
Items 201–300 of 1,000
Ugurel, S., Spassova, I., Wohlfarth, J., Drusio, C., Cherouny, A., Melior, A., Sucker, A., Zimmer, L., Ritter, C., Schadendorf, D., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02341-9 · Cited by 84
Bretz, A. C., Parnitzke, U., Kronthaler, K., Dreker, T., Bartz, R., Hermann, F., Ammendola, A., Wulff, T., & Hamm, S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0745-3 · Cited by 83
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 84
Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Quandt, D., Zucht, H. D., Amann, A., Wulf-Goldenberg, A., Borrebaeck, C. A. K., Cannarile, M. A., Lambrechts, D., Oberacher, H., Garrett, J., Nayak, T. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17397 · Cited by 84
Update on Merkel Cell Carcinoma
Harms, P. W. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.05.004 · Cited by 81
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
Hailemichael, Y., Woods, A. N., Fu, T., He, Q., Nielsen, M. C., Hasan, F., Roszik, J., Xiao, Z., Vianden, C., Khong, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93303 · Cited by 81
Engels, E. A. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15495 · Cited by 82
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma
Yanik, E. L., Kaunitz, G. J., Cottrell, T. R., Succaria, F., McMiller, T. L., Ascierto, M. L., Esandrio, J., Xu, H., Ogurtsova, A., Cornish, T. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0115 · Cited by 78
Self-citationGirardi, D. M., Silva, A. C. B., Rêgo, J. F. M., Coudry, R. A., & Riechelmann, R. P. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.002 · Cited by 78
Simon, S., Voillet, V., Vignard, V., Wu, Z., Dabrowski, C., Jouand, N., Beauvais, T., Khammari, A., Braudeau, C., Josien, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001631 · Cited by 79
Self-citationT‐cell subsets in the skin and their role in inflammatory skin disorders
Krohn, I. K., Aerts, J. L., Breckpot, K., Goyvaerts, C., Knol, E. F., van Wijk, F., & Gutermuth, J. (2021) · Allergy · doi:10.1111/all.15104 · Cited by 81
Park, D. E., Cheng, J., McGrath, J. P., Lim, M. Y., Cushman, C. H., Swanson, S. K., Tillgren, M. L., Paulo, J. A., Gokhale, P. C., Florens, L. A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0503-2 · Cited by 77
Delyon, J., Biard, L., Renaud, M., Resche‐Rigon, M., LeGoff, J., Dalle, S., Heidelberger, V., Meda, L. D., Toullec, L., Carcelain, G., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00097-3 · Cited by 76
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
Prieux‐Klotz, C., Dior, M., Damotte, D., Dréanic, J., Brieau, B., Brézault, C., Abitbol, V., Chaussade, S., & Coriat, R. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0495-4 · Cited by 76
Xu, C., Zhang, Y., Rolfe, A., Hernández, V. M., Guzman, W., Kradjian, G., Marelli, B., Qin, G., Qi, J., Wang, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0483 · Cited by 78
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
Domingo‐Musibay, E., Murugan, P. J., Giubellino, A., Sharma, S., Steinberger, D. J., Yuan, J., Hunt, M. A., Lou, E., & Miller, J. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0357-3 · Cited by 76
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers
Rinke, A., & Gress, T. M. (2017) · Digestion · doi:10.1159/000454761 · Cited by 75
Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
Lee, M., Samstein, R. M., Valero, C., Chan, T. A.-T., & Morris, L. G. T. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1631136 · Cited by 76
Correlates of immune and clinical activity of novel cancer vaccines
van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 76
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A., & Rosner, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3079 · Cited by 75
Targeting cancer stem cells in the clinic: Current status and perspectives
Annett, S., & Robson, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.001 · Cited by 76
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 76
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 76
Vandeven, N. A., Lewis, C. W., Makarov, V., Riaz, N., Paulson, K. G., Hippe, D. S., Bestick, A., Doumani, R., Marx, T., Takagishi, S. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1678 · Cited by 74
Self-citationMerkel Cell Carcinoma: Therapeutic Update and Emerging Therapies
Villani, A., Fabbrocini, G., Costa, C., Annunziata, M. C., & Scalvenzi, M. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-0288-z · Cited by 75
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Spassova, I., Ugurel, S., Terheyden, P. A. M., Sucker, A., Hassel, J. C., Ritter, C., Kubat, L., Habermann, D., Farahpour, F., Saeedghalati, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2244 · Cited by 73
Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 73
Li, G., Gao, Y., Gong, C., Han, Z., Qiang, L., Tai, Z., Tian, J., & Gao, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b13354 · Cited by 71
Shamir, E. R., Devine, W. P., Pekmezci, M., Umetsu, S. E., Krings, G., Federman, S., Cho, S., Saunders, T. A., Jen, K., Bergsland, E. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0131-6 · Cited by 71
Paulson, K. G., Lahman, M. C., Chapuis, A. G., & Brownell, I. (2019) · International Immunology · doi:10.1093/intimm/dxz012 · Cited by 71
Ferrata, M., Schad, A., Zimmer, S., Musholt, T. J., Bahr‐Hamm, K., Kuenzel, J., Becker, S., Springer, E., Roth, W., Weber, M. M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00343 · Cited by 71
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13081 · Cited by 72
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Gallo, M., Muscogiuri, G., Felicetti, F., Faggiano, A., Trimarchi, F., Arvat, E., Vigneri, R., & Colao, A. (2017) · Metabolism · doi:10.1016/j.metabol.2017.09.013 · Cited by 72
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 76
Glioblastoma multiforme: novel therapeutic targets
Muir, M. T., Gopakumar, S., Traylor, J. I., Lee, S., & Rao, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1762568 · Cited by 71
Gudd, C. L. C., Au, L., Triantafyllou, E., Shum, B., Liu, T., Nathwani, R., Kumar, N., Mukherjee, S. K., Dhar, A., Woollard, K. J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.008 · Cited by 69
Calvani, J., Terada, M., Lesaffre, C., Eloudzeri, M., Lamarthée, B., Burger, C., Tinel, C., Anglicheau, D., Vermorel, A., Couzi, L., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15699 · Cited by 69
Management of Non-melanoma Skin Cancer in Transplant Recipients
Collins, L. B., Asfour, L., Stephany, M., Lear, J. T., & Stasko, T. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.08.005 · Cited by 68
Elias, A. W., Kasi, P. M., Stauffer, J. A., Thiel, D. D., Colibaseanu, D., Mody, K., Joseph, R. W., & Bagaria, S. P. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00121 · Cited by 68
Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients
Sims, J. R., Grotz, T. E., Pockaj, B. A., Joseph, R. W., Foote, R. L., Otley, C. C., Weaver, A. L., Jakub, J. W., & Price, D. L. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.10.005 · Cited by 68
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson, L. M., Howard, J. E. F., Cruz, J. L. G., Jackson, C. C., Barnett, C. M. E., Overton, L., Liu, H. Y.-H., Ladwa, R., Simpson, F., McGrath, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32869 · Cited by 67
Polyomavirus‐driven Merkel cell carcinoma: Prospects for therapeutic vaccine development
Tabachnick‐Cherny, S., Pulliam, T., Church, C. D., Koelle, D. M., & Nghiem, P. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23190 · Cited by 69
Self-citationYeong, J. P.-S., Tan, T. J., Chow, Z. L., Cheng, Q., Lee, B. T. K., Seet, A. O. L., Lim, J. X., Lim, J. C. T., Ong, C. C. H., Thike, A. A., et al. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-206252 · Cited by 67
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Adhikaree, J., Moreno-Vicente, J., Kaur, A. P., Jackson, A. M., & Patel, P. M. (2020) · Cells · doi:10.3390/cells9020263 · Cited by 68
Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options
Hernandez, L. E. D. L. C., Mohsin, N., Yaghi, M., Frech, F. S., Dreyfuss, I., & Nouri, K. (2021) · Dermatologic Therapy · doi:10.1111/dth.15292 · Cited by 68
Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma
Lam, J. H., Ng, H. H. M., Lim, C. J., Sim, X. N., Malavasi, F., Li, H., Loh, J. J. H., Sabai, K., Kim, J.-K., Ong, C. C. H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02093 · Cited by 66
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 65
Xie, Z., Liu, L., Lin, X., Xie, X., Gu, Y., Liu, M., Zhang, J., Ouyang, M., Lizaso, A., Zhang, H., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0391-9 · Cited by 65
Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy
Sobol, I., Chen, C. L., Mahmood, S., & Borczuk, A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0447-oa · Cited by 67
Recent advances in understanding antitumor immunity
Munhoz, R. R., & Postow, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9356.1 · Cited by 70
Whither Radioimmunotherapy: To Be or Not To Be?
Green, D. J., & Press, O. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2523 · Cited by 64
Panda, A., Betigeri, A. M., Subramanian, K., Ross, J. S., Pavlick, D. C., Ali, S. M., Markowski, P. A., Silk, A. W., Kaufman, H. L., Lattime, E. C., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00146 · Cited by 64
Selective reactivation of STING signaling to target Merkel cell carcinoma
Liu, W., Kim, G. B., Krump, N. A., Zhou, Y., Riley, J. L., & You, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919690117 · Cited by 65
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma
Leiendecker, L., Jung, P. S., Kręcioch, I., Neumann, T., Schleiffer, A., Mechtler, K., Wiesner, T., & Obenauf, A. C. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012525 · Cited by 65
Image-guided intratumoral immunotherapy: Developing a clinically practical technology
Som, A., Rosenboom, J., Chandler, A., Sheth, R. A., & Wehrenberg-Klee, E. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114505 · Cited by 63
Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma
Schadendorf, D., Nghiem, P., Bhatia, S., Hauschild, A., Saïag, P., Mahnke, L. A., Hariharan, S., & Kaufman, H. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338237 · Cited by 66
Self-citationTreatment resistance in urothelial carcinoma: an evolutionary perspective
Vlachostergios, P. J., & Faltas, B. M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0026-y · Cited by 62
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Mazzotti, L., Gaimari, A., Bravaccini, S., Maltoni, R., Cerchione, C., Juan, M., González‐Navarro, E. A., Pasetto, A., Silva, D. N., Ancarani, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158590 · Cited by 64
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
Schmults, C. D., Blitzblau, R. C., Aasi, S. Z., Alam, M., Amini, A., Bibee, K., Bolotin, D., Bordeaux, J. S., Chen, P.-L., Contreras, C. M., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0002 · Cited by 61
Self-citationMerkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy
Amaral, T. M. S., Leiter, U., & Garbe, C. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9433-0 · Cited by 60
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Xue, Y., & Thakuria, M. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.08.002 · Cited by 60
Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis
Pasquali, S., Chiarion‐Sileni, V., Rossi, C. R., & D, S. M. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.006 · Cited by 60
PD-L1 Expression in Pancreatic Cancer
Zheng, L. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw304 · Cited by 59
Chang, J., Zhu, G. A., Cheung, C., Li, S., Kim, J., & Chang, A. L. S. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.5062 · Cited by 61
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Fan, K., Ritter, C., Nghiem, P., Blom, A., Verhaegen, M. E., Dlugosz, A. A., Ødum, N., Woetmann, A., Tothill, R. W., Hicks, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1184 · Cited by 62
Self-citationClinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients
Singh, N., Alexander, N. A., Lachance, K., Lewis, C. W., McEvoy, A. M., Akaike, G., Byrd, D. R., Behnia, S., Bhatia, S., Paulson, K. G., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.07.065 · Cited by 59
Self-citationDrug-induced cardiac toxicity and adverse drug reactions, a narrative review
Destère, A., Merino, D., Lavrut, T., Rocher, F., Viard, D., Drici, M., & Gérard, A. O. (2023) · Therapies · doi:10.1016/j.therap.2023.10.008 · Cited by 61
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
Soo, R. A., Kim, H. R., Asuncion, B. R., Fazreen, Z., Omar, M. F. M., Herrera, M. C., Lim, J. S. Y., Sia, G., Soong, R., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.008 · Cited by 60
Lee, J. S.-J., Durham, A. B., Bichakjian, C. K., Harms, P. W., Hayman, J. A., McLean, S. A., Harms, K. L., & Burns, W. R. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-7072-7 · Cited by 58
Zhang, W., Wang, W., Han, X., Gao, H.-L., Xu, S., Li, S., Li, T., Xu, H., Li, H., Ye, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001188 · Cited by 58
A Century of Radiation Therapy and Adaptive Immunity
Schaue, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00431 · Cited by 57
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
Immunotherapeutic approaches in nasopharyngeal carcinoma
Chow, J. C., Ngan, R. K., Cheung, K., & Cho, W. C. S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1650910 · Cited by 57
Hauschild, A., Eichstaedt, J., Möbus, L., Kähler, K. C., Weichenthal, M., Schwarz, T., & Weidinger, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.026 · Cited by 56
Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies
Biersmith, M. A., Tong, M., Guha, A., Simonetti, O. P., & Addison, D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013755 · Cited by 56
Complete spontaneous regression of Merkel cell carcinoma (1986–2016): a 30 year perspective
Walsh, N. M. G. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12812 · Cited by 55
Budczies, J., Mechtersheimer, G., Denkert, C., Klauschen, F., Mughal, S. S., Chudasama, P., Bockmayr, M. L., Jöhrens, K., Endris, V., Lier, A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1279777 · Cited by 56
Merkel Cell Carcinoma: An Update and Immunotherapy
Uchi, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00048 · Cited by 55
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Chan, I. S., Bhatia, S., Kaufman, H. L., & Lipson, E. J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0335-9 · Cited by 55
Self-citationEpigenetic tuning of PD-1 expression improves exhausted T cell function and viral control
Weiss, S. A., Huang, A. Y., Fung, M. E., Martínez, D., Chen, C.-Y., LaSalle, T. J., Miller, B. C., Scharer, C. D., Hegde, M., Nguyen, T. H., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01961-3 · Cited by 56
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Peng, L.-X., & Wu, Y.-L. L. C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.106 · Cited by 57
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
Shibata, T., Lieblong, B. J., Sasagawa, T., & Nakagawa, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.07.001 · Cited by 54
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman, M. M., Behl, T., Islam, M. R., Islam, M. R., Islam, M. R., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27123798 · Cited by 55
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Colen, R. R., Rolfo, C. D., Ak, M., Ayoub, M., Ahmed, S., Elshafeey, N. A., Mamindla, P., Zinn, P. O., Ng, C. S., Vikram, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001752 · Cited by 54
Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma
Cook, M. M., Baker, K. K., Redman, M. W., Lachance, K., Nguyen, M. H., Parvathaneni, U., Bhatia, S., Nghiem, P., & Tseng, Y. D. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000482 · Cited by 53
Self-citationTetzlaff, M. T., & Harms, P. W. (2019) · Modern Pathology · doi:10.1038/s41379-019-0394-6 · Cited by 53
Zheng, Y., Kim, R., Yu, T., Gayle, J. A., Wassel, C. L., Dreyfus, J., Phatak, H. M., & George, S. (2021) · The Oncologist · doi:10.1002/onco.13918 · Cited by 54
Xu, Y., Liao, W., Luo, Q., Yang, D., & Pan, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.761046 · Cited by 52
Minibeam Radiation Therapy Treatment (MBRT): Commissioning and First Clinical Implementation
Grams, M. P., Mateus, C. Q., Mashayekhi, M., Mutter, R. W., Djonov, V., Fazzari, J., Xiao, H., Frechette, K. M., Wentworth, A. J., Morris, J. M., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.06.035 · Cited by 52
Leshem, Y., & Pastan, I. H. (2019) · Toxins · doi:10.3390/toxins11010020 · Cited by 52
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
Dillman, R. O. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1244149 · Cited by 52
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Li, Y., Zhang, Y., Cao, G., Zheng, X., Sun, C., Wei, H., Tian, Z., Xiao, W., Sun, R., & Sun, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01112-3 · Cited by 51
Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
Zaggana, E., Konstantinou, M. P., Krasagakis, G. H., de Bree, E., Kalpakis, K., Mavroudis, D., & Krasagakis, K. (2022) · Cancers · doi:10.3390/cancers15010103 · Cited by 51
Acquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 51
Merkel cell carcinoma of the eyelid: A review
North, V. S., Habib, L. A., & Yoon, M. K. (2019) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2019.03.002 · Cited by 52
Metadata
- Authors
- Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., Shantha, E. M., Sharfman, W. H., Sharon, E., Shemanski, L. R., Shinohara, M. M., Sunshine, J. C., Taube, J. M., Thompson, J. A., Townson, S. M., Yearley, J. H., Topalian, S. L., & Cheever, M. A.
- Affiliations
- Johns Hopkins University (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Mount Sinai Hospital (US)
- ORCID
- Nghiem, Paul T.
- Bhatia, Shailender
- Lipson, Evan J.
- Kudchadkar, Ragini R.
- Miller, Natalie J.
- Berry, Sneha
- Chartash, Elliot K.
- Daud, Adil
- Fling, Steven P.
- Friedlander, Philip A.
- Kluger, Harriet M.
- Lundgren, Lisa
- Margolin, Kim
- Pardoll, Drew M.
- Reddy, Sunil A.
- Sharfman, William H.
- Sharon, Elad
- Shinohara, Michi M.
- Sunshine, Joel C.
- Taube, Janis M.
- Thompson, John A.
- Topalian, Suzanne L.
- Cheever, Martin A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-30
- Volume
- 374
- Issue
- 26
- Pages
- 2542-2552
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4927341
- OpenAlex
- W2339890238
- Cited by
- 1,258
- References
- 42
- Citations by year
- 2026: 40 · 2025: 68 · 2024: 76 · 2023: 86 · 2022: 104 · 2021: 141 · 2020: 166 · 2019: 172 · 2018: 187 · 2017: 174 · 2016: 40
- FWCI
- 103.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (5u01ca154967-06)
- National Cancer Institute (U01-CA-154967, R01CA162522, 1U01CA154967, K24CA139052, UM1CA154967, R01CA142779, P30CA006973)
- National Institute of General Medical Sciences (T32GM007266)
- Topics
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- Merkel cell carcinoma, pembrolizumab, anti-PD-1 therapy, immune checkpoint inhibitors, Merkel cell polyomavirus, PD-L1 expression, first-line therapy, objective response rate, progression-free survival, cutaneous squamous cell carcinoma, immune-related adverse events, treatment-related adverse events, treatment duration, drug safety and efficacy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Skin Neoplasms, Carcinoma, Merkel Cell, Disease-Free Survival, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
